Vimarsana
Biggest News Aggregation in the World

Page 22 - Major Project News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Major Project. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Major Project Today - Breaking & Trending Today

From General Manager: New signs of development in South West Rocks - Vimarsana News

From General Manager: New signs of development in South West Rocks

The South West Rocks community will see new growth this Summer, with Council aware of a number of sizeable residential developments taking big steps

MMC-GAMUDA WINS BACK-TO-BACK AWARDS - Vimarsana News

MMC-GAMUDA WINS BACK-TO-BACK AWARDS

MMC-GAMUDA, the underground works package contractor for the MRT Putrajaya Line, is ending the year on a high after sweeping two prestigious international awards for tunnelling excellence, with a possibility of scooping a third one on Wednesday.

Innovent Biologics and Ascentage Pharma Announce the China NMPA Approval for China's First Third-Generation BCR-ABL Inhibitor Olverembatinib for the Treatment of Chronic Myeloid Leukemia - Vimarsana News

Innovent Biologics and Ascentage Pharma Announce the China NMPA Approval for China's First Third-Generation BCR-ABL Inhibitor Olverembatinib for the Treatment of Chronic Myeloid Leukemia

/PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...

Innovent Biologics and Ascentage Pharma Announce the China NMPA Approval for China's First Third-Generation BCR-ABL Inhibitor Olverembatinib for the Treatment of Chronic Myeloid Leukemia - Vimarsana News

Innovent Biologics and Ascentage Pharma Announce the China NMPA Approval for China's First Third-Generation BCR-ABL Inhibitor Olverembatinib for the Treatment of Chronic Myeloid Leukemia

/PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...

Ascentage Pharma and Innovent Biologics Announce Approval for China's First Third-Generation BCR-ABL TKI Olverembatinib, Marking a Clinical Breakthrough in the Treatment of Chronic Myeloid Leukemia - Vimarsana News

Ascentage Pharma and Innovent Biologics Announce Approval for China's First Third-Generation BCR-ABL TKI Olverembatinib, Marking a Clinical Breakthrough in the Treatment of Chronic Myeloid Leukemia

/PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB),...